Phalanx Biotech recently launched its CytoOneArray.
The Taiwanese company designed the chromosomal microarray for prenatal and postnatal detection of microdeletions and microduplications related to congenital disorders, especially developmental and intellectual delay disorders. According to Phalanx, CytoOneArray is capable of detecting 264 clinically confirmed disease regions and 41 subtelomere regions.
CEO Shengwan Lee said in a statement that CytoOneArray is the "first in a series" of chromosomal microarray products, and noted that the release occured at a "time when cytogeneticists are adopting chromosomal microarray as a first-tier clinical diagnostic test."
To design CytoOneArray, Phalanx worked with "leading cytogeneticists" in Taiwan. Following a curation process of disease regions, the company designed probes to cover 90 percent of published microdeletions and microduplications associated with developmental and intellectual delay disorders.
BioArray News discussed Phalanx's entry into the chromosomal array market earlier this year (BAN 3/13/2012)